Reck, M., Spira, A. I., Besse, B., Wolf, J. M., Skoulidis, F., Borghaei, H., . . . Ramalingam, S. S. (2020). 1416TiP CodeBreak 200: A phase III multicenter study of sotorasib (AMG 510), a KRAS(G12C) inhibitor, versus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC) harboring KRAS p.G12C mutation.
Չիկագոյի ոճի (17րդ խմբ.) մեջբերումReck, Martin, et al. 1416TiP CodeBreak 200: A Phase III Multicenter Study of Sotorasib (AMG 510), a KRAS(G12C) Inhibitor, Versus Docetaxel in Patients with Previously Treated Advanced Non-small Cell Lung Cancer (NSCLC) Harboring KRAS P.G12C Mutation. 2020.
MLA (9րդ խմբ.) ՄեջբերումReck, Martin, et al. 1416TiP CodeBreak 200: A Phase III Multicenter Study of Sotorasib (AMG 510), a KRAS(G12C) Inhibitor, Versus Docetaxel in Patients with Previously Treated Advanced Non-small Cell Lung Cancer (NSCLC) Harboring KRAS P.G12C Mutation. 2020.